High-sensitivity, low-cost point of care testing for infection to combat antimicrobial resistance by reducing over-prescription of antibiotics
High-sensitivity, low-cost point of care testing for infection to combat antimicrobial resistance by reducing over-prescription of antibiotics
批准号:
10028217
负责人:
金额:
$76.08万
依托单位国家:
英国
项目类别:
Collaborative R&D
财政年份:
2022
资助国家:
英国
项目状态:
已结题
起止时间:
2022 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Antimicrobial resistance (AMR), is a healthcare emergency. It is estimated to cause 12,000 deaths in the UK and 700,000 globally, and is forecast by the WHO to cause 10 million annual deaths globally by 2050, with the same economic impact as the 2008-2009 global financial crisis.Whereas antibiotics must be prescribed to treats serious infections, the growth in antibiotic resistance is accelerated by over-prescription of antibiotics, where antibiotics are unnecessarily prescribed, which is estimated to be at least 20% of more than 20 million NHS antibiotic prescriptions made each year, predominantly in primary care.Procalcitonin, 'PCT', is the optimal choice for diagnosing infections, compared to many other biomarkers which indicate general inflammation. It is highly specific and is detectable throughout the lifetime of an infection, provided testing provides sufficient sensitivity.For reliable testing of PCT to be utilised as an aid to prescribe antibiotics it must be highly-sensitive it must be rapid low-cost to be widely used. While POC devices exist for PCT, they lack sufficient sensitivity to be reliably used and have high individual test cost preventing widespread use.Osler seek to overcome these challenges with a true high-sensitivity, low-cost PCT test cartridge. This will be enabled using Osler's high-sensitivity electrochemical assay technology, coupled with genuine low-cost manufacturing methods, including from those used in blood glucose and lateral flow devices.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
骨髓微环境中正常造血干/祖细胞新亚群IL7Rα(-)LSK(low)细胞延缓急性髓系白血病进程的作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:王震毅
-
依托单位:
MSCEN聚集体抑制CD127low单核细胞铜死亡治疗SLE 的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:耿林玉
-
依托单位:
脐带间充质干细胞微囊联合低能量冲击波治疗神经损伤性ED的机制研究
-
批准号:82371631
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:卢慕峻
-
依托单位:
LIPUS促进微环境巨噬细胞释放CCL2诱导尿道周围平滑肌祖细胞定植与分化的机制研究
-
批准号:82370780
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:夏术阶
-
依托单位:
Ni-20Cr合金梯度纳米结构的低温构筑及其腐蚀行为研究
-
批准号:52301123
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2023
-
负责人:郭晓开
-
依托单位:
新型PDL1+CXCR2low中性粒细胞在脉络膜新生血管中的作用及机制研究
-
批准号:82271095
-
项目类别:面上项目
-
资助金额:56万元
-
批准年份:2022
-
负责人:柳夏林
-
依托单位:
CD9+CD55low脂肪前体细胞介导高脂诱导脂肪组织炎症和2型糖尿病的作用和机制研究
-
批准号:82270883
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:毕艳
-
依托单位:
CD21low/-CD23-B细胞亚群在间质干细胞治疗慢性移植物抗宿主病中的作用机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:陈小湧
-
依托单位:
探究Msi1+Lgr5neg/low肠道干细胞抵抗辐射并驱动肠上皮再生的新机制
-
批准号:82270588
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:吕聪
-
依托单位:
m6A去甲基化酶FTO通过稳定BRD9介导表观重塑在HIF2α(low/-)肾透明细胞癌中的作用机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:54.7万元
-
批准年份:2021
-
负责人:徐丹枫
-
依托单位: